Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

OpenAI’s October 6 release of 722 math solutions signals automation in verifiable research; cryptography’s absence drew Alex’s post-quantum risk warning.Meta’s active memory and 3.6 billion daily users offer reach, but Alex says Muse trails on cost.Alex forecasts the $1.8 billion virtual-cell initiative could yield cures for 5,000 diseases within two to three years, pending FDA acceptance.

Sarah Guo × Elad Gil × Greg Brockman

Brockman says AI is now creating reusable mathematical insight, with almost 400 important open problems solved through unexpected combinations of ideas.Drug development offers the clearest disruption case: a roughly 15-year, $1.5 billion process could accelerate in literature review, simulations, experiments, and regulatory writing, but biological data and long-term outcomes remain constraints.As code approaches near-zero cost, Brockman predicts cybersecurity spending should “far exceed software spending,” while OpenAI’s defender’s window and recurring model-led security testing remain catalysts to monitor.

Ian Quigley × Brandon Anderson × RJ Honicky

Leash’s reported edge is low-cost, carefully characterized data: its ten-person operation developed about 2,000 protein constructs and ran roughly 5,000 screens.On the hardest Kaggle split, none of roughly 2,000 teams beat chance, exposing how poorly models transfer to distant chemistry.Language agents now test hypotheses instantly against measured compounds, but coverage remains limited and potency calibration unfinished.

David Senra × Ben Wilson

Ben Wilson’s stage-four metastatic neuroendocrine carcinoma had an initial one-year prognosis; chemotherapy pushed it back, and he is starting tarlatamab.His framework is breaking trade-offs: NeXT faltered pursuing every priority, while Jobs’s iPod accepted feature gaps for user experience.Tarlatamab’s durability is unclear; clinical trials may follow, and he is exploring a custom mRNA vaccine to enhance it.

Molly O'Shea × Nworah Ayogu

Thrive’s healthcare thesis is that AI may shift bottlenecks from molecule generation to validation, trials, manufacturing, and commercialization.Cadence cites 25% fewer hospitalizations, over-80% more controlled-blood-pressure patients, nearly one-point lower A1C, and $2.5 million in weekly Medicare savings across 100,000+ monitored patients.Neuralink and OpenAI show upside, while clinical processes and manufacturing capacity remain unresolved constraints.

Pushmeet Kohli × Sal Candido × Brandon Anderson

AlphaFold 2 reproduced PDB-deposited structures, but ground state, dynamics, function, and design remain open, shifting the frontier toward richer biological context and raw cryo-EM data.Metagenomic sequences show useful scaling depends on statistical fit rather than volume, while calibrated pLDDT and clearer bottlenecks—not a 10x or 100x timetable—determine whether AI can safely accelerate drug development.

Patrick O'Shaughnessy × Andrew Huberman

Sleep is the near-term neurotechnology wedge because users already accept physiological measurement, while an eye mask reportedly measures REM, induces sleep-promoting eye movements, and amplifies REM, with related technology expected in roughly seven to 12 months.Huberman predicts Meta, OpenAI, Anthropic, and Elon’s Neuralink effort will converge on neural read/write biotech, but missing models of memory and thought, plus a possible 2027-28 downturn in optimization content, remain key risks.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Richard Socher

Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.

Graig Suvannavejh × Sam Fazeli × Eric Schmidt × Brian Skorney

Biotech’s 27% XBI gain through September masks a punishing ownership unwind, as underowned and heavily shorted names offset specialist-fund selling.Regeneron-Sanofi’s $1 billion upfront and AstraZeneca’s $2 billion Summit investment show strategic capital is flowing, but HARMONi-3 remains a potentially historic binary event.China-origin deals and Lilly’s obesity data sharpen competition, while financing, durability, tolerability, and endpoint risk still dictate outcomes.

Jonathan Siddharth × Molly O'Shea

Healthcare AI has crossed O'Shea’s threshold for measurable impact, with biological and chemical models, laboratory robotics and simulations targeting drug development’s high failure rates.After a decade building licenses, networks and care infrastructure, Devoted Health tripled in size, halved operating expenses and significantly increased EBITDA, while China’s rising pharmaceutical research share leaves domestic research and regulatory capacity as risks to monitor.